We address the challenge of detecting the contribution of noncoding mutation to disease with a deeplearning-based framework that predicts specific regulatory effects and deleterious disease impact of genetic variants. Applying this framework to 1,790 Autism Spectrum Disorder (ASD) simplex families reveals autism disease causality of noncoding mutations by demonstrating that ASD probands harbor transcriptional (TRDs) and post-transcriptional (RRDs) regulation-disrupting mutations of significantly higher functional impact than unaffected siblings. Importantly, we detect this significant noncoding contribution at each level, transcriptional and post-transcriptional, independently. Further analysis suggests involvement of noncoding mutations in synaptic transmission and neuronal development and points to functional relevance of progenitor cell types to ASD. We demonstrate that sequences carrying prioritized proband de novo mutations possess transcriptional regulatory activity and drive expression differentially, and propose a potential link between the quantitative impact of noncoding versus coding mutations in ASD individuals to their IQ. Our predictive genomics framework illuminates the role of noncoding variants in ASD, prioritizes high impact transcriptional and post-transcriptional regulatory mutations for further study, and is broadly applicable to complex human diseases.
excess of proband mutations, as it is otherwise hard to distinguish disease-relevant excess of mutations from irrelevant biological and technical variation, such as genetic background differences or artificial biases from sequencing, variant calling, and filtering procedures. These WGS data were generated in several phases, providing a natural replication framework, with a discovery cohort of 530 families and a validation cohort of 1,260 families.
However, even with the study design with matched control individuals, detecting the noncoding contribution is still challenging, and establishing the role of the vast noncoding space in the genetic basis of autism remains elusive. A recent study in fact demonstrated that even when considering a wide variety of possible functional annotation categories (e.g. mutations in known regulatory sites, mutations at the location of known histone marks, mutations near ASD-or disease-relevant gene sets), no significant noncoding ASD-proband-specific signal was observed 15 . The challenge is the lack of a systematic approach that reliably identifies impactful noncoding mutations, analogous to the genetic codon code which allows demarcation of protein coding mutations that likely disrupt protein function from synonymous ones. This challenge is shared in studies of other psychiatric diseases with complex genetic bases, such as intellectual disabilities and schizophrenia 16, 17 . In fact, little is known about the contribution of noncoding rare variants or de novo mutations to human diseases 18 beyond the less common cases with Mendelian inheritance patterns 5 .
To address this challenge, we used biochemical data demarcating DNA and RNA binding protien interactions to train and deploy a deep convolutional-neural-network-based framework that predicts the functional and disease impact of 127,140 de novo noncoding mutations in the SSC. Our framework estimates, with single nucleotide resolution, the quantitative impact of each variant on 2,002 specific transcriptional and 232 specific post-transcriptional regulatory features, including histone marks, transcription factors and RNA-binding protein (RBP) profiles. Using this approach, we discovered a significantly elevated burden of disruptive de novo transcriptional-regulatory disrupting (TRD) and RBP-regulatory disrupting (RRD) proband mutations in ASD, providing evidence for causality of noncoding regulatory mutations in autism. We also identify specific pathways and relevant cell types affected by these mutations, and demonstrate differential effect of coding and noncoding mutations on IQ in individuals ASD.
Results

Contribution of transcriptional regulatory noncoding mutations to ASD
Analysis of noncoding effect contribution in ASD is challenging due to the difficulty of assessing which noncoding mutations are functional, and further, which of those contribute to the disease phenotype. For predicting the regulatory impact of noncoding mutations, we constructed a deep convolutional networkbased framework to directly model the functional impact of each mutation and provide a biochemical interpretation including the disruption of transcription factor binding and chromatin mark establishment at the DNA level and of RBP binding at the RNA level ( Fig. S1) . At the DNA level, the framework includes cell-type specific transcriptional regulatory effect models from over 2,000 genome-wide histone marks, transcription factor binding and chromatin accessibility profiles (from ENCODE and Roadmap Epigenomics projects 19, 20 ) , extending the deep learning-based method that we described previously 9 with redesigned architecture (leading to significantly improved performance, p=6.7x10 -123 , Wilcoxon rank-sum test). At the RNA level, our deep learning-based method was trained on the precise biochemical profiles of over 230 RBP-RNA interactions (CLIP) known to regulate a wide range of post-transcriptional regulation, including RNA splicing, localization and stability. At both transcriptional and posttranscriptional levels, our models are accurate and robust in whole chromosome holdout evaluations ( Fig   S1) . Our models utilize a large sequence context to provide single nucleotide resolution to our predictions, while also capturing dependencies and interactions between various biochemical factors (e.g. histone marks or RBPs). This approach is data-driven, does not rely on known sequence information, such as transcription factor binding motifs, and it can predict impact of any mutation regardless of whether it has been previously observed, which is essential for the analysis of ASD de novo mutations.
Finally, to link the biochemical disruption caused by a variant with phenotypic impact, we trained a regularized linear model using a set of curated human disease regulatory mutations 5 (HGMD) and rare variants from healthy individuals in the 1,000 Genomes populations 21 to generate a predicted disease impact score for each autism variant based on its predicted transcriptional and post-transcriptional regulatory effects.
By directly modeling functional impact of de novo mutations derived from 7,097 whole genomes from the SSC cohort with our framework, we detected a significant difference in probands compared to unaffected siblings, at both the transcriptional (p=5.6x10 -4 , one-side wilcoxon rank-sum test for all) and post-transcriptional (p=3.0x10 -4 ) levels ( Fig. 1) . We first observed proband-specific TRD and RRD burden in the discovery cohort (SSC phase 1 sequencing of 530 families), and this was subsequently replicated in an independent replication cohort (SSC sequencing of 1,260 remaining families). Although this difference is significant in every cohort (discovery, replication, combined), the dysregulation effect size increases with expected ASD relevance -e.g. variants near or within ExAC strongly constrained genes 22 (pLI > 0.9 from ExAC, 3,230 genes, TRD p=2.6x10 -3 ; RRD p=1.8x10 -3 ), in genes previously predicted to be associated with ASD 21 (2,582 genes, TRD p=1.7x10 -5 ) or biochemically identified as FMRP targets 23 (1,246 genes, RRD p=1.8x10 -4 ) ( Fig. 1B-D) . Although previous work has demonstrated the challenge of detecting any significant proband-specific signal even with highly specific subsets of genes or functional genomics regions, we find significant proband-specific signal even across all 127,140 de novo variants at sufficient cohort size (TRD p=9.4x10 -3 , RRD -all transcribed variants p=1.3x10 -3 ). Wilcoxon rank sum test (one-sided) was used for computing the significance levels. All predicted disease impact scores were normalized by subtracting average predicted disease impact scores of sibling mutations for each comparison (95% CI).
(C) Biological replication of genome-wide noncoding burden of de novo SNVs altering transcriptional and posttranscriptional regulation. The initial detection of higher disease scores in ASD probands in our discovery cohort of 530 simplex families (phase 1 of sequencing) was independently reproduced in a later generated replication cohort (1,260 families). Disease impact scores for all genes (n DNA,discovery =20,890, n RNA,discovery =1,412, n DNA,replication =48,438, n RNA,replication =3,181), ExAC LoF intolerant (n DNA,discovery =4,466, n RNA,discovery =394, n DNA,replication =10,407, n RNA,replication =991), ASD-relevant (DNA, n discovery =4,223, n replication =9,768), FMRP target (RNA, n discovery =207, n replication =509) genes.
Functional landscape of noncoding ASD-associated de novo mutations
We then investigated which processes and pathways are impacted by de novo noncoding mutations in ASD. Such analysis is challenging because in addition to the variability in functional impact of mutations, ASD probands appear highly heterogeneous in underlying causal genetic perturbations 24 and single mutations could cause a widespread effect on downstream genes. Thus to detect genes and pathways relevant to the pathogenicity of ASD TRD and RRD mutations, we developed a network-based functional enrichment approach, which we coined NDEA (Network-neighborhood Differential Enrichment Analysis) ( Fig. S2) . We used a brain-specific functional network that probabilistically integrates a large compendium of public omics data (e.g. expression, PPI, motifs) to infer how likely two genes are to act together in a biological process 25 . When applied to ASD de novo mutations, the NDEA approach identifies genes whose functional network neighborhood is enriched for gene-neighbors with stronger predicted disease impact in proband mutations compared to sibling mutations ( Supplementary   Table 1 ).
Globally, NDEA enrichment analysis pointed to a proband-specific role for noncoding mutations in affecting neuronal development, including in synaptic transmission and chromatin regulation (Figure   2A ), consistent with processes previously associated with ASD based on protein-coding variants 2 . Genes with significant NDEA enrichment were specifically involved in neurogensis and grouped into two functionally coherent clusters with Louvain community detection algorithm ( Figure 2B) . The synaptic cluster is enriched in ion channels and receptors involved in neurogenesis (p=5.61x10 -38 ), synaptic signaling (p=4.80x10 -35 ) and synapse organization (p=1.52x10 -18 ), including previously known ASDassociated genes such as those involved in synapse organization genes SHANK2, NLGN2, NRXN2, synaptic signaling genes NTRK2 and NTRK3, ion channel genes CACNA1A/C/E/G, KCNQ2, and neurotransmission genes SYNGAP1, GABRB3, GRIA1, GRIN2A 26 . The synapse cluster is also significantly enriched for plasma membrane proteins (p=3.88x10 -24 ). In contrast, the chromatin cluster, representing chromatin regulation related processes, displayed an overrepresentation of nucleoplasm (p=2.11x10 -9 ) proteins, with diverse functional roles including covalent chromatin modification (p=2.46x10 -9 ), chromatin organization(5.17x10 -8 ) and regulation of neurogenesis (p=6.44x10 -5 ). The chromatin cluster also includes many known ASD-associated genes such as chromatin remodeling protein CHD8, chromatin modifiers KMT2A, KDM6B, and Parkinson's disease causal mutation gene PINK1 27 which is also associated with ASD 26 . Overall, our results demonstrate pathway-level TRD and RRD mutation burden and identify distinct network level hot spots for high impact de novo mutations. (B) Genes with significant network neighborhood excess of high-impact proband mutations form two functionally coherent clusters (see annotations for representative enriched gene sets in each cluster, full list is in Supplementary   Table 3 ). The brain functional network is visualized by computing two-dimensional embeddings with t-SNE (Methods). Genes, but not network edges, are shown for visualization clarity. The network differential enrichment analysis (NDEA) was performed on disease impact scores of all mutations within 100kb to representative TSSs (DNA) and all intronic mutations within 400nt to exon boundary (RNA). Clustering was performed with Louvain community clustering. All genes in the two clusters shown are with FDR < 0.1.
Cell type regulatory effect specificity of de novo mutations in autism
We then examined the cell type specificity of the predicted effects from the noncoding proband mutations in ASD as our regulatory effect models are tissue-specific due to training on profiles from a wide range of tissues and cell types. This provided a unique opportunity to probe the cell type of origin of ASD signal by identifying in which cell types the predicted regulatory effects show the most significant excess in proband mutations compared to unaffected sibling mutations. To avoid biases of representation of cell types in the training regulatory profile compendium, we performed a cross-tissue comparison restricted to the four histone marks (H3K4me3, H3K4me1, H3K27ac, and H3K9ac) that were systematically measured in 34 cell types ( Fig. 3) . Overall, we observed upranking of stem cells and progenitor cell types with respect to difference in proband vs sibling effect of noncoding mutations. Notably, eleven of the top fifteen ranked cell types are embryonic stem and progenitor cells, including neural progenitor cells (cell type-specific FDR<0.05). This suggests that noncoding ASD disease mutations may function in early neuronal development, consistent with the similar trend found in protein coding mutations in ASD patients 28 . 
13
Experimental study of ASD noncoding mutation effects on gene expression
Our analysis identified new candidate noncoding disease mutations with potential impact on ASD through regulation of gene expression. In order to add further evidence to a set of high confidence causal mutations, we experimentally studied allele-specific effects of predicted high-impact mutations in cellbased assays. Thirty four genomic regions showed strong transcriptional activity with 94% proband variants (32 variants) showing robust differential activity (Fig. 4, Methods) ; demonstrating that our prioritized de novo TRD mutations do indeed lie in regions with transcriptional regulatory potential and the predicted effects translate to measurable allele-specific expression effects. Among these genes with the demonstrated strong differential activity mutations, NEUROG1 is an important regulator of initiation of neuronal differentiation and in the NDEA analysis had significant network neighborhood proband excess (p=8.5e-4), and DLGAP2 a guanylate kinase localized to the post-synaptic density in neurons.
Mutations near HES1 and FEZF1 also carried significant differential effect on activator activities: neurogenin, HES, and FEZF family transcription factors act in concert during development, both receiving and sending inputs to Wnt and Notch signaling in the developing central nervous system and interestingly, the gut, to control stem cell fate decisions [28] [29] [30] [31] [32] ; and Wnt and Notch pathways have been previously associated with autism 24, 33 . SDC2 is a synaptic syndecan protein involved in dendritic spine formation and synaptic maturation, and a structural variant near the 3' end of the gene was reported in an autistic individual (reviewed in Saied-Santiago, 2017 34 ). Thus, our method identified alleles of high predicted impact that do indeed show changes in transcriptional regulatory activity in cells. Since many autism genes are under strong evolutionary selection, only effects exerted through (more subtle) gene expression changes may be observable because complete loss of function mutations may be lethal. This implies that further study of the prioritized noncoding regulatory mutations will yield insights into the range of dysregulations associated with autism. 
Association of IQ with de novo noncoding mutations in ASD individuals
Intellectual disability is estimated to impact 40-60% of autism children 35 , and ASD individuals can over-inherit common variants associated with high education attainment 36 . The genetic basis of this variation is not well understood. Despite the genetic complexity observed in association with ASD proband IQ, past efforts to identify mutations that contribute to ASD found that these mutations are also negatively correlated with IQ. Specifically, in analyses of exome sequencing data from different ASD cohorts, a significant association of higher burden of de novo coding likely-gene-disrupting (LGD) (also shown for WGS data in Fig. S3 ) and large copy number variation (CNV) mutations with lower proband IQ was observed 2,7 .
For de novo noncoding mutations analyzed in this study, we observe a significant association between noncoding mutations and IQ in ASD individuals. Intriguingly, we find that higher IQ ASD individuals have a higher burden of TRDs, whereas for ExAC constrained genes lower IQ ASD individuals have a higher burden of RRDs (Fig. 5) . Thus, it is tempting to speculate that while mutations that are damaging to the protein through coding (LGD or large CNVs) or RNA processing (RRD) disruption are likely to increase the risk of lower IQ in ASD context, mutations affecting transcriptional regulation (TRDs) can affect ASD without the coupled negative effect on IQ. More severe TRD mutations were observed in probands with higher IQs and more severe RRD mutations were observed in probands with lower IQs. Proband IQ was shown on the x-axis and the normalized z-scores for maximum feature-level effect (absolute probability changes) of mutation was represented by the y-axis. The fitted linear regression line and 95% confidence interval was shown. All comparisons in this plot were made for mutations within 100kb of the representative TSSs for DNA and within 400nts of a AS regulatory region exon of a pLI>0.9 gene for RNA).
Conclusions
Even with great strides in understanding the causes of ASD by sequencing and phenotyping of multiple cohorts in the recent years, much of the genetic basis underlying autism remains undiscovered. While a number of coding variants have been associated with ASD, no systematic evidence of de novo noncoding effect has been observed. Here we present a novel deep-learning based approach for quantitatively assessing the impact of noncoding mutations on human disease. Our approach addresses the statistical challenge of detecting the contribution of noncoding mutations by predicting their specific effects on transcriptional and post-transcriptional level. This approach is general and can be applied to study contributions of noncoding mutations to any complex disease or phenotype.
Here, we apply it to ASD using the 1,790 whole genome sequenced families from the Simons Simplex Collection, and for the first time demonstrate significant proband-specific signal in regulatory noncoding space. Importantly, we detect this signal not only at the transcriptional level, but also find significant proband-specific RRD burden. There's been limited evidence for disease contribution of mutations disrupting post-transcriptional mechanisms outside of the canonical splice sites. We demonstrate significant ASD disease association at the de novo mutation level for variants impacting a large collection Although previous work established that severe genetic perturbations such as CNVs and LGDs associated with ASD link to more severe intellectual disability and lower IQ, we show that this relationship is not universal for all ASD causal genetic perturbations. This is important as it provides evidence that ASD and IQ can be genetically uncoupled at de novo mutation level.
Our analyses also demonstrate the potential of predicting disease phenotypes from genetic information including de novo noncoding mutations. We provide a resource for further research into understanding the mechanism of noncoding impact on ASD, including computationally prioritized TRD and RRD mutations with strong predicted regulatory effects, as well as potentially disease contributing ASD proband mutations with experimentally confirmed effects (Supplementary Table 4-5 ).
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Methods
De novo mutation calling and filtering
The Simons Simplex Collection WGS data was made available via Simons Foundation Autism Research Initiative (SFARI), and was processed to generate variant calls via the standard GATK pipeline. To call de novo single nucleotide substitutions, inherited mutations were removed, and candidate de novo mutations were selected from the GATK variant calls where the alleles were not present in parents and the parents were homozygous with the same allele. DNMFilter classifier was then used to score each candidate de novo mutation and a threshold of probability > 0.75 was applied to phase 1 and 2 and a threshold of probability > 0.5 was applied to phase 3 to obtain a comparable number of high-confidence DNM calls across phases.
The DNMFilter 49 classifier was trained with an expanded training set combining the original training standards with the verified DNMs from the pilot WGS studies for the 40 SSC families families 16 . De novo mutations calls within the repeat regions from RepeatMasker 50 were removed. The WGS DNM calls were compared against exome sequencing de novo mutations calls and previously validated SSC de novo mutations 37 : 91.1% of the exome sequencing mutations calls and 93.2% of the validated mutations were rediscovered in our mutations calls. Further filtering was then applied to remove variants that were called in more than one SSC families.
Training of DNA transcriptional regulatory effects and RNA posttranscriptional effects models
For training the transcriptional regulatory effects model, training labels, such as histone marks, transcription factors, and DNase I profiles, were processed from uniformly processed ENCODE and Roadmap Epigenomics data releases. The training procedure is as described in Zhou and Troyanskaya 20 with the following modifications. The model architecture was extended to double the number of convolution layers for increased model depth (see Supplementary Note 2 for details). Input features were expanded to include all of the released Roadmap Epigenomics histone marks and DNase I profiles, resulting in 2,002 total features (Supplementary Table 6 ) compared to 919 original features.
For training the post-transcriptional regulatory effects model, we utilized the DeepSEA network architecture and training procedure with RNA-binding protein (RBP) profiles as training labels (full list of parameters used in model is in Supplementary Note 2). We uniformly process RNA features composed of 231 CLIP binding profiles for 82 unique RBPs (ENCODE and previously published CLIP datasets) and a branchpoint mapping profile as input features (full list of experimental features listed in Supplementary Table 7 ). CLIP data processing followed our previous detailed pipeline 38 , all CLIP peaks with p-value < 0.1 were used for training with an additional filter requirement of two-fold enrichment over input for ENCODE eCLIP data. In contrast to the DeepSEA, only transcribed genic regions were considered as training labels for the post-transcriptional regulatory effects model. Specifically, all gene regions defined by Ensembl (mouse build 80, human build 75) were split into 50nt bins in the transcribed strand sequence. For each sequence bin, RBP profiles that overlapped more than half were assigned a positive label for the corresponding RBP model. Negative labels for a given RBP model were assigned to sequence bins where other RBP's non-overlapping peaks were observed. Note that our deep learning models, both transcriptional and post-transcriptional, does not use any mutation data for training, thus it can predict impacts for any mutation regardless of whether it has been previously observed.
Disease impact score prediction
We used curated disease regulatory mutations and rare variants from healthy individuals to train a model that prioritizes likely disease-impacting mutations based on the predicted transcriptional or posttranscriptional regulatory impacts of these mutations. As positive examples, we used regulatory mutations curated in the Human Gene Mutation Database (HGMD). As negative examples of background mutations, we used rare variants that were only observed once within the healthy individuals from the 1000 Genomes project 21 . Absolute predicted probability differences computed by the convolutional network transcriptional regulatory effects model (described above) were used as input features for each of 
Discriminative transcriptional regulatory features and cell type relevance ranking
For each of the 2,002 transcriptional feature sequence predictors, we tested for significant differences between predicted proband mutation effects and sibling mutation effects within 100kb to any representative TSS. Transcriptional regulatory feature effects were computed as the difference between transcriptional regulatory feature probabilities computed for the reference (sibling) allele and the alternative (proband) allele.
For ranking the cell type relevance of noncoding ASD mutations, we used 34 cell types that each had all four sequence-based chromatin predictors (H3K4me3, H3K4me1, H3K27ac, and H3K9ac). We ranked the cell types based on minimum Benjamini-Hochberg-adjusted p-value for proband predicted effect excess compared to siblings across the four histone mark predictors.
Gene sets and resources
Gene sets used included: ASD exome sequencing LGD genes compiled by Krishnan et al. 24 , top decile predicted ASD relevant genes from Krishnan et al. 24 , and constrained gene lists with pLI scores from the ExAC project 22 .
We determined the representative TSS for each gene based on FANTOM CAGE transcription initiation counts relative to GENCODE gene models. Specifically, a CAGE peak is associated to a GENCODE gene if it is within 1000bp from a GENCODE v24 annotated transcription start site 39, 40 . Peaks within 1000bp to rRNA, snRNA, snoRNA or tRNA genes were removed to avoid confusion. Next, we selected the most abundant CAGE peak for each gene, and took the TSS position reported for the CAGE peak as the selected representative TSS for the Gene. For genes with no CAGE peaks assigned, we kept the GENCODE annotated gene start position as the representative TSS. FANTOM CAGE peak abundance data were downloaded at http://fantom.gsc.riken.jp/5/datafiles/latest/extra/CAGE_peaks/ and the CAGE read counts were aggregated over all FANTOM 5 tissue or cell types. GENCODE v24 annotation lifted to GRCh37 coordinates were downloaded from http://www.gencodegenes.org/releases/24lift37.html. All chromatin profiles used from ENCODE and Roadmap Epigenomics projects were listed in Supplementary Table 6 . The HGMD mutations are from HGMD professional version 2018.1.
Human exons that are alternatively spliced (AS) were obtained from a recent study that has examined publicly available human RNA-seq data to annotate an extensive catalog of AS events 41 exon AS exon types. All selected exon-flanking intronic regions (400nts from exon boundary) were collapsed into a final set of genomic intervals used to subset SNVs that are located within alternative splicing regulatory region. An extend list of FMRP targets were used derived from 3 additional biological replicates and including the original 7 replicates FMRP-CLIP 23 (1,246 genes, FDR < 0.05).
Network differential enrichment analysis (NDEA)
Brain-specific functional relationship networks integrate a wide-range of functional genomic data in a tissue-specific manner and predicted the probability of functional association between any pair of genes 25 .
This network was filtered to only include edges with >0.01 probability (above Bayesian prior) to reduce the impact of noisy low-confidence edges.
For each gene , we designed the neighborhood excess significance test which is a specific form of weighted t-test, specifically the t statistic is computed by ! ! are the unbiased estimates of population variance of ! ! and ! ! . ! ! and ! ! are the effective sample sizes of proband and sibling mutations after network-based weighting for gene i.
Under null hypothesis of the two groups have no difference, the above t statistic approximately follows a t-distribution with the following degree of freedom:
For testing significance difference between proband and sibling mutations, mutations within 100kb of the representative TSS of all genes and all intronic mutations within 400bp to exon boundary were included in this analysis. RNA model disease impact score z-scores were used as the mutation score for intronic mutations within 400bp to exon boundary and DNA model disease impact score z-scores were used for other mutations.
For gene set level NDEA, we create a meta-node that represents all genes that are annotated to the gene set (e.g. GO term). Then, the average of network edge scores for all genes in the meta-node is used as the weights to any given gene not part of the gene set. GO term annotations were pooled from human (EBI 5/9/2017), mouse (MGI 5/26/2017) and rat (RGD 4/8/2017). Query GO terms were obtained from the merged set of curated GO consortium 42 slims from Generic, Synapse, ChEMBL, and supplemented by PANTHER 43 GO-slim and terms from NIGO 44 .
Network visualization and clustering
For network visualization, we computed a two-dimensional embedding with t-SNE 45 by directly taking a distance matrix of all pairs of genes as the input. The distance matrix was computed as -log(probability) from the edge probability score matrix in the brain-specific functional relationship network. The Barnes-Hut t-SNE algorithm implemented in the Rtsne package was used for the computation. Louvain community clustering were performed on the subnetwork containing all protein-coding genes with top 10% NDEA FDR.
Cloning of Variant Allele Genomic Regions
All genomic sequences were retrieved from the hg19 human genome assembly. For experimental testing, we selected variants of high predicted disease impact scores larger than 0.5 and included mutations near genes with evidence for ASD association, including those with LGD mutations (e.g. CACNA2D3) and a proximal structural variant (e.g. SDC2). For each allele (sibling or proband), we either cloned 230 nucleotides of genomic sequence amplified from proband lymphoblastoid cell lines or used fragments synthesized by Genewiz ( Supplementary Table 5 ). In both cases, 15 nucleotide flanks on 5' and 3' ends matched each flank of the plasmid cloning sites. The 5' sequence was TGGCCGGTACCTGAG and the 3' sequence was ATCAAGATCTGGCCT. Synthesized fragments were cut with KpnI and BglII and cloned into pGL4.23 (Promega) cut with the same enzymes. PCR-amplified genomic DNA was cloned into pNL3.1 blunt-end cut with EcoRV and Eco53kI using GeneArtCloning method from Thermofisher Scientific. All constructs were verified by Sanger sequencing. Table 5 ), and 4ng of pNL3.1 NanoLuc (shrimp luciferase) plasmid, for normalization of transfection conditions. 42 hours after transfection, luminescence for each plasmid was detected with the Promega NanoGlo Dual Luciferase assay system (N1630) and BioTek Synergy plate reader. Four to six replicates per variant were tested in each experiment. For each sequence tested, the ratio of firefly luminescence (ASD allele) to NanoLuc luminescence (transfection control) was calculated and then normalized to empty vector (pGL4.23 with no insert). Statistics were calculated from fold over empty vector values from each biological replicate. High-confidence differentially-expressing alleles were defined by their ability to show the same effect in each biological replicate (n=3, minimum), drive higher than control empty-vector level gene expression, and the two alleles had significantly different level of luciferase activity by two-sided t-test. For presentation of the data, we normalized the fold over empty vector value of the proband allele to that of the sibling allele.
Luciferase Reporter Assays
Transcriptional and post-transcriptional effect association with IQ
To analyze the association between transcriptional or post-transcriptional effect with IQ, we computed the maximum probability differences across features for each mutation, and tested for its association with IQ using linear regression with two-sided Wald test on the slope coefficient. For DNA analysis, we use all variants that are within 100kb from the TSS. For RNA analysis, we restrict the mutations to genes with ExAC pLI >0.9 and are intronic within 400nts to an exon in an alternatively splicing regulatory region.
